Go to The Journal of Clinical Investigation
  • About
  • Editors
  • Consulting Editors
  • For authors
  • Publication ethics
  • Transfers
  • Advertising
  • Job board
  • Contact
  • Current issue
  • Past issues
  • By specialty
    • COVID-19
    • Cardiology
    • Immunology
    • Metabolism
    • Nephrology
    • Oncology
    • Pulmonology
    • All ...
  • Videos
  • Collections
    • Resource and Technical Advances
    • Clinical Medicine
    • Reviews
    • Editorials
    • Perspectives
    • Top read articles
  • JCI This Month
    • Current issue
    • Past issues

  • Current issue
  • Past issues
  • Specialties
  • In-Press Preview
  • Concise Communication
  • Editorials
  • Viewpoint
  • Top read articles
  • About
  • Editors
  • Consulting Editors
  • For authors
  • Publication ethics
  • Transfers
  • Advertising
  • Job board
  • Contact
Basigin deficiency prevents anaplerosis and ameliorates insulin resistance and hepatosteatosis
Akihiro Ryuge, … , Shoichi Maruyama, Kenji Kadomatsu
Akihiro Ryuge, … , Shoichi Maruyama, Kenji Kadomatsu
Published October 22, 2021
Citation Information: JCI Insight. 2021;6(20):e142464. https://doi.org/10.1172/jci.insight.142464.
View: Text | PDF
Research Article Hepatology Metabolism

Basigin deficiency prevents anaplerosis and ameliorates insulin resistance and hepatosteatosis

  • Text
  • PDF
Abstract

Monocarboxylates, such as lactate and pyruvate, are precursors for biosynthetic pathways, including those for glucose, lipids, and amino acids via the tricarboxylic acid (TCA) cycle and adjacent metabolic networks. The transportation of monocarboxylates across the cellular membrane is performed primarily by monocarboxylate transporters (MCTs), the membrane localization and stabilization of which are facilitated by the transmembrane protein basigin (BSG). Here, we demonstrate that the MCT/BSG axis sits at a crucial intersection of cellular metabolism. Abolishment of MCT1 in the plasma membrane was achieved by Bsg depletion, which led to gluconeogenesis impairment via preventing the influx of lactate and pyruvate into the cell, consequently suppressing the TCA cycle. This net anaplerosis suppression was compensated in part by the increased utilization of glycogenic amino acids (e.g., alanine and glutamine) into the TCA cycle and by activated ketogenesis through fatty acid β-oxidation. Complementary to these observations, hyperglycemia and hepatic steatosis induced by a high-fat diet were ameliorated in Bsg-deficient mice. Furthermore, Bsg deficiency significantly improved insulin resistance induced by a high-fat diet. Taken together, the plasma membrane–selective modulation of lactate and pyruvate transport through BSG inhibition could potentiate metabolic flexibility to treat metabolic diseases.

Authors

Akihiro Ryuge, Tomoki Kosugi, Kayaho Maeda, Ryoichi Banno, Yang Gou, Kei Zaitsu, Takanori Ito, Yuka Sato, Akiyoshi Hirayama, Shoma Tsubota, Takashi Honda, Kazuki Nakajima, Tomoya Ozaki, Kunio Kondoh, Kazuo Takahashi, Noritoshi Kato, Takuji Ishimoto, Tomoyoshi Soga, Takahiko Nakagawa, Teruhiko Koike, Hiroshi Arima, Yukio Yuzawa, Yasuhiko Minokoshi, Shoichi Maruyama, Kenji Kadomatsu

×

Figure 6

Bsg deficiency protects mice from HFD-induced insulin resistance.

Options: View larger image (or click on image) Download as PowerPoint

Bsg deficiency protects mice from HFD-induced insulin resistance.
(A) S...
(A) Schematic diagram of the in vivo experiments used to test the effects of 16 weeks of nutritional overburden. (B) Fasting blood glucose levels in Bsg+/+ and Bsg–/– mice maintained for 16 weeks on standard CD or HFD (n = 5–6/genotype and diet combination). White columns and circles, Bsg+/+ mice; gray columns and black circles, Bsg–/– mice. Scatter plots display the data for individual mice. (C) HOMA-IR in HFD-fed Bsg+/+ and Bsg–/– mice (n = 6/genotype). (D and E) Glucose excursions and the AUC scores in Bsg+/+ and Bsg–/– mice (maintained on CD or HFD for 16 weeks) when subjected to (D) IP glucose tolerance tests or (E) oral glucose tolerance tests (n = 10–12/genotype and diet combination). (F) Glucose excursions and the AUC scores in Bsg+/+ or Bsg–/– mice (maintained on HFD for 16 weeks) when administered IP with insulin (0.6 units/kg body weight) (n = 9/genotype). (G) GIR in 8- to 12-week-old Bsg+/+ or Bsg–/– mice after insulin infusion in the hyperinsulinemic-euglycemic clamp study (n = 4/genotype). (H) Akt phosphorylation in isolated hepatocytes and C2C12 cells in the absence or presence of insulin as demonstrated by Western blotting analysis. (I) Representative micrographs of H&E-stained sections showing hepatic steatosis in Bsg+/+ and Bsg–/– mice. Scale bar: 200 μm. (J–L) Liver weight (J), serum ALT values (K), and liver TG content (L) in CD-fed or HFD-fed Bsg+/+ and Bsg–/– mice (n = 5–8/genotype and diet combination). For all relevant panels, data are presented as means ± SEM. *P < 0.05, **P < 0.01, for the comparison of Bsg+/+ and Bsg–/– at the indicated time point (2-tailed unpaired Student’s t test).

Copyright © 2022 American Society for Clinical Investigation
ISSN 2379-3708

Sign up for email alerts